ArticlePloS one2026
28-day all-cause mortality and associated factors in cancer patients with bacteremia at a peruvian referral center.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe global prevalence of cancer has increased in recent decades. Cancer patients are especially vulnerable to invasive infections like bacteremia. In Peru, the rising incidence of bloodstream infections caused by resistant pathogens has become a major public health issue. There is limited information about this complication in the Peruvian cancer population. No previous local studies have assessed mortality or explored the impact of antimicrobial resistance on patient outcomes in this group.
methodsThis study aimed to evaluate 28-day all-cause mortality and its associated factors among cancer patients with bacteremia at a referral cancer center in Lima. We retrospectively analyzed data from first episodes of bacteremia in hospitalized adult patients between July 2020 and June 2024.
resultsA total of 293 patients were included in the study. The mean age was 65.4 ± 15.3 years, and 53.9% were female. Most patients had solid tumors (84.3%) and active disease (91.8%), with digestive cancers being the most common (34.1%). The 28-day all-cause mortality rate was 32.1%. Empirical antimicrobial therapy was appropriate in 80.7% of cases. Gram-negative bacteria (GNB) predominated (82.8%), with Escherichia coli being the most frequently isolated pathogen (45.7%). Among Enterobacteriaceae, 43.6% were extended-spectrum beta-lactamase (ESBL) producers, and 3.3% of GNB were carbapenem-resistant. Multivariable Poisson regression identified the Charlson Comorbidity Index (RR 1.1; 95% CI 1.1-1.2), sepsis (RR 2.3; 95% CI 1.3-3.8), septic shock (RR 3.0; 95% CI 1.9-4.6), respiratory failure (RR 1.6; 95% CI 1.2-2.2), Coagulase-negative Staphylococci (CoNS) bacteremia (RR 1.8; 95% CI 1.2-2.6) and primary source (RR 2.8; 95% CI 1.5-5.1) as independent factors associated with increased 28-day mortality.
conclusionAt this cancer referral center, one-third of patients with bacteremia died within 28 days. Mortality was primarily caused by the severity of infection, comorbidities and specific bacteremia characteristics, rather than antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.